Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

PD-L1 monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibody-Drug Conjugates (ADCs) (1) PD-1/PD-L1 (54) Apoptosis (5) Autophagy (1) CD19 (1) CD3 (1) COX (1) CTLA-4 (3) DNA-PK (1) DNA/RNA Synthesis (1) EGFR (1) IFNAR (2) Interleukin Related (2) Mitochondrial Metabolism (1) PERK (1) Ras (1) SHP1 (1) TNF Receptor (3) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (52) Inflammation/Immunology (17) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Targets Recommended: PD-1/PD-L1 ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-P9904

Atezolizumab Maximum Cited Publications 36 Publications Verification MPDL3280A; RG-7446; RO-5541267	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P9919

Durvalumab 5+ Cited Publications MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-108730

Avelumab 5+ Cited Publications Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .

HY-108730A

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .

HY-P9919A

Durvalumab (anti-PD-L1) 5+ Cited Publications MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity .

HY-P9978

Toripalimab JS-001	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against *PD-1. Toripalimab is able to bind to PD-1* and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-177439

HLX43	Antibody-Drug Conjugates (ADCs) PD-1/PD-L1	Cancer
HLX43 is an antibody-drug conjugate (ADC) targeting *PD-L1. HLX43 consists of a human monoclonal* antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .

HY-P99052

Tislelizumab 3 Publications Verification BGB-A317	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99457

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against *PD-1* .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071)	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine *PD-L1/B7-H1* IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

HY-P99943

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Cancer
Erfonrilimab (KN-046) is a monoclonal antibody targeting *PD-L1/CTLA-4*. Erfonrilimab blocks the *PD-L1* and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

HY-P99203

Cemiplimab REGN-2810; SAR-439684	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against *CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3* and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or *PD-L1* on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

HY-P99641

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research .

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-P9972

Spartalizumab PDR001	PD-1/PD-L1 IFNAR	Cancer
Spartalizumab is a humanized *PD-1* IgG4 monoclonal antibody, with a K_d of 0.83 nM for human *PD-1* and a K_d of 0.93 nM for cynomolgus monkey *PD-1. Spartalizumab binds to PD-1* and blocks its interaction with the ligands *PD-L1* and *PD-L2. Spartalizumab induces increased IFNγ* release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P99723

Manelimab BCD-135	PD-1/PD-L1	Cancer
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .

HY-P991193

NGM-438	TNF Receptor	Cancer
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a K_a of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to *PD-1* blockade, increases the content of intratumoral CD8 ⁺ T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction of PD-L1* and PD-1. Garivulimab has antitumor activity .

HY-P99957

Zeluvalimab AMG-404	PD-1/PD-L1	Cancer
Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer .

HY-P991084

TQB-2858	PD-1/PD-L1	Cancer
TQB-2858 is a bifunctional fusion protein composed of a monoclonal antibody against *PD-L1* fused with the extracellular domain of TGF-β receptor. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS) .

HY-P991151

Opamtistomig	PD-1/PD-L1 TNF Receptor	Cancer
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against *PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1* pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P990014

Danburstotug IMC-001; STI-3031	PD-1/PD-L1	Inflammation/Immunology Cancer
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .

HY-P99639

Geptanolimab Genolimzumab; APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .

HY-P990698

Umizortamig	PD-1/PD-L1 EGFR	Inflammation/Immunology
Umizortamig is an anti-CD3E/EGFR/TNFRSF9/PD-L1/CD3G monoclonal antibody .

HY-P9S0062

Rosnilimab (Mouse IgG2a)	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a, Rosnilimab. Rosnilimab is a *PD-1* agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) can be used in research related to ulcerative colitis .

HY-P990072

Lipustobart LZM-009	PD-1/PD-L1	Cancer
Lipustobart is an IgG4-kappa, anti-*PDCD1 (programmed cell death 1, PD1, PD-1, CD279)* humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .

HY-P991147

Ledostomig	PD-1/PD-L1	Cancer
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1* with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-P991353

Sym-021	PD-1/PD-L1	Cancer
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .

HY-P991355

PDL-GEX	PD-1/PD-L1	Cancer
PDL-GEX is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274. PDL*-GEX can be used in cancer research .

HY-P991357

STT-001	PD-1/PD-L1	Cancer
STT-001 is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274*. STT-001 can be used in Solid tumours research .

HY-P991354

GR-1405	PD-1/PD-L1	Cancer
GR-1405 is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1*-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .

HY-P992168

ABM101	PD-1/PD-L1	Inflammation/Immunology
ABM101 is a humanized monoclonal antibody targeting *PD-L1*.

Cat. No.	상품명

HY-L031

Small Molecule Immuno-Oncology Compound Library

788 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 788 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	상품명	Target	Research Area	Image